Table 2.

Predicted and observed clearances of ADCs by three animal species allometric scaling.

Drugs	Coefficient	Exponent	Observed	Predicted	Ratio *
DSTP3086S (total antibody)
Simple	11.7	1.06	574	1052	1.83
Brain weight	155.7	2.06	574	709	1.23
T-DM1 (total antibody)
Simple	5.37	0.89	343	236	0.69
T-DM1 (conjugate)
Simple	14.3	0.91	600	683	1.14
DNIB0600A (rat data were added to Li et al.’s original data) (total antibody)
Simple	13.7	1.07	854	1313	1.54
Brain weight	182.5	2.08	854	886	1.04
Brentuximab vedotin (mouse data were added to Li et al.’s original data) (total antibody)
Simple	13	0.90	742	595	0.80
Thiomab (total antibody)
Simple	6.5	1.03	200	517	2.58
Brain weight	86.9	2.03	200	345	1.73
Thiomab (conjugate)
Simple	18.3	0.95	759	1027	1.35
Polatuzumab vedotin (total antibody) (rat data were added to Li et al.’s original data) (total antibody)
Simple	8.91	1.06	1015	795	0.78
Brain weight	119	2.06	1015	537	0.53
Anti-5T4 (total antibody) **
Simple	9.9	0.82	360	323	0.90
Anti-5T4 (conjugate) **
Simple	17.3	0.85	700	640	0.91

* Predicted Ratio = Predicted/Observed. ** The human clearance of Anti-5T4 was based on a 4.34 mg/kg human dose for both total antibody and conjugate. ** The human clearance of Anti-5T4 was calculated by extracting the mean concentration–time data from Figure 2 in the original study.